MHRA Yellow Card vape reports: how adult UK buyers should interpret the June 2026 update

For adult UK vape buyers, the short version is this: MHRA's June 2026 Yellow Card update is useful safety-monitoring information, but it is not a list of proven vaping harms, not a risk-rate table and not a product approval list.

The MHRA consumer advice page was last updated on 18 June 2026, with the Electronic Cigarette Analysis Profile refreshed to a data lock of 31 May 2026. MHRA says people can report suspected side effects after using an e-cigarette product, plus other safety concerns with e-cigarettes or refill containers, through the Yellow Card scheme. It also says reports are added to a vigilance database and assessed by specialist teams for possible patterns of concern (MHRA advice for consumers).

That matters because Yellow Card data is easy to over-read. A suspected report can be important. It can help regulators look for signals. But a report appearing in the Analysis Profile does not, by itself, prove that the vape product caused the reported effect. For adult buyers, the practical lesson is evidence literacy: check official sources, keep product details, report genuine concerns properly and avoid treating headline numbers as if they were confirmed diagnoses or incidence rates.

MHRA's consumer advice page records an update on 18 June 2026: the Electronic Cigarette Analysis Profile was updated to 31.05.2026 (MHRA advice for consumers). The Analysis Profile is a table of spontaneous suspected adverse reaction entries involving nicotine-containing e-cigarettes reported to MHRA through Yellow Card by healthcare professionals and members of the public.

The 31 May 2026 profile lists 1,817 reaction entries and 7 fatal entries across the MedDRA reaction categories in the document (Electronic Cigarette Analysis Profile up to 31.05.2026). Those numbers need careful wording. They are reaction entries in suspected reporting data. They are not a count of proven cases caused by vaping, and they are not a rate of risk among UK vapers.

There are two common mistakes to avoid. The first is minimising the reports because they are not proof. That misses the point of vigilance systems: early reports can still help regulators investigate possible patterns. The second is treating the totals as settled proof that a product or behaviour caused a specific outcome. MHRA's own interpretation guidance says Analysis Prints can help identify possible safety issues, but they do not provide a complete overview of risk and cannot prove causation on their own (MHRA E-Cigarette Analysis Print guidance).

Yellow Card is a reporting and monitoring route. It is designed to collect suspected adverse reactions and safety concerns so that MHRA can review them for possible patterns. MHRA says submitted reports go into its vigilance database and are assessed by scientists, doctors and pharmacists; if potential safety concerns are identified, MHRA can take regulatory action (MHRA advice for consumers).

What Yellow Card can do is help regulators spot signals. If several reports describe similar concerns, or if a report includes strong product details, timing and clinical context, it may give assessors something useful to examine. Reports can also help point attention towards defective products, fake products or wider compliance problems.

What Yellow Card cannot do, by itself, is prove that a nicotine-containing vape caused a particular reaction. The MHRA interpretation guide explains that the likelihood of experiencing an adverse reaction cannot be estimated from an Analysis Print because there is limited information about how many people used an e-cigarette without a reaction. It also says reports are submitted on suspicion, and the existence of a report does not necessarily mean the e-cigarette caused the reaction (MHRA E-Cigarette Analysis Print guidance).

That caveat is especially important with serious entries. A fatal entry in a suspected adverse reaction dataset is not the same thing as a confirmed death caused by vaping. It is a serious report that belongs in a monitoring system and needs careful assessment, not a headline to be stripped of context.

The Yellow Card e-cigarette page says that if you have an adverse reaction or safety concern about a nicotine-containing e-cigarette, also known as a vape, and/or e-liquid, you should report it to the Yellow Card scheme (MHRA Yellow Card: e-cigarettes). The same page describes an adverse reaction as a harmful physical or mental effect.

The reporting scope is not limited to a product making someone feel unwell. MHRA also points to concerns involving defective or fake e-cigarettes and e-liquids where they cause an adverse reaction or are a safety concern (MHRA Yellow Card: e-cigarettes). The November 2023 MHRA Drug Safety Update says healthcare professionals and members of the public can report suspected adverse reactions and safety concerns to Yellow Card, and it asks for as much detail as possible to support safety vigilance (MHRA Drug Safety Update, 23 November 2023).

For everyday adult buyers, it helps to separate different routes:

• Use Yellow Card for suspected adverse reactions and vape safety concerns involving nicotine-containing e-cigarettes and/or e-liquids.
• Use the retailer or manufacturer for ordinary returns, warranty faults or order problems that do not raise a safety concern.
• Use local Trading Standards routes where you suspect illegal supply or non-compliant products. MHRA's consumer advice says reports of other product safety or quality concerns associated with e-cigarettes are shared with local Trading Standards officers and the Office for Health Improvement and Disparities as appropriate (MHRA advice for consumers).

For practical background on identifying suspicious products, see our guide to how to spot a fake disposable vape.

The most useful report is usually the most specific one. If you are an adult user reporting a suspected reaction or safety concern, gather the details before packaging is thrown away or the product name is forgotten.

1. Keep the product packaging if possible, especially the box, pod, bottle or device label.
2. Note the product name, brand, nicotine strength, flavour name and format.
3. Record the batch number and ECID where available.
4. Write down when the product was first used, how often it was used and whether use changed over time.
5. Note when the suspected reaction or safety concern began, including the time between use and the first concern.
6. Include relevant context such as other medicines, substances or medical history where it is relevant and you are comfortable sharing it.
7. If the issue is urgent or you are worried about symptoms, seek appropriate medical help through NHS 111, a pharmacist, a GP, a clinician or emergency services as the situation requires.

MHRA's Drug Safety Update asks for details such as product name or brand, strength, flavour, batch number, ECID, duration and frequency of use, time to onset, medical history and relevant concomitant medicines or substances when reporting suspected adverse reactions and safety concerns (MHRA Drug Safety Update, 23 November 2023).

Keeping packaging is not just useful for Yellow Card. It is also useful for checking whether a product matches expected UK labelling and notification details. For more on label checks, read our guide to UK vape packaging rules in 2026.

Another point in the June 2026 consumer advice is easy to misunderstand: MHRA publication is a compliance check for supply, not a broad safety endorsement.

MHRA says consumers can check whether e-cigarette products have been successfully notified using the MHRA publication home page, and that products are not compliant for supply until the notification has been published on the relevant list for Great Britain and/or Northern Ireland. It also says consumers should only purchase nicotine-containing e-cigarette products included on MHRA publication pages (MHRA advice for consumers).

That does not mean MHRA is saying every published product is risk-free, suitable for every adult or incapable of attracting a Yellow Card report. It means the product has reached the relevant publication stage in the notification system. The wider GOV.UK consumer product guidance says nicotine-containing e-cigarettes and e-liquids must be notified and published by MHRA before they can be sold, as part of the UK requirements for these products (GOV.UK e-cigarette consumer product regulations).

This distinction is why official-source checking matters. A social post might say a vape is "MHRA approved" or claim that a Yellow Card entry proves a product caused harm. Both framings can mislead. For a broader method, see UK vape rule changes in 2026: how to check what is confirmed.

MHRA is central to nicotine-containing e-cigarette notification and Yellow Card vigilance, but it is not the only body involved in UK vape regulation. The MHRA regulator profile lists multiple bodies and responsibilities across the system, including Office for Health Improvement and Disparities, OPSS, environmental regulators and Trading Standards functions (MHRA e-cigarette and vape products regulator profile).

For consumer products, GOV.UK says the MHRA is the competent authority for the UK's notification scheme for nicotine-containing vaping products in Great Britain and Northern Ireland, working with other regulatory bodies under Part 6 of the Tobacco and Related Products Regulations 2016 as amended (GOV.UK e-cigarette consumer product regulations). The MHRA Drug Safety Update also states that MHRA assesses notification requirements before products come to market, while Trading Standards are responsible for enforcing safety and quality once products have been supplied to the UK market (MHRA Drug Safety Update, 23 November 2023).

The core UK product limits still matter for adult buyers. GOV.UK says the requirements restrict e-cigarette tanks to no more than 2ml, restrict nicotine-containing refill containers for sale to 10ml, restrict e-liquids to no more than 20mg/ml nicotine strength, require child-resistant and tamper-evident packaging for nicotine-containing products or their packaging, and include labelling requirements and warnings (GOV.UK e-cigarette consumer product regulations). We explain those limits in plain English in TPD regulations explained.

None of this should be read as a workaround guide. If a product is over the legal nicotine strength limit, uses an oversized nicotine-containing tank or pod, lacks required labelling, or cannot be matched to the relevant notification publication route, the answer is not to find a loophole. The adult-buyer answer is to avoid it, keep evidence if you already bought it, and use the appropriate reporting or enforcement route.

Use the June 2026 update as a prompt to be more precise, not more anxious. For adult UK buyers, the practical checklist is straightforward:

• Check that nicotine-containing products are on the relevant MHRA publication pages before buying, where applicable (MHRA advice for consumers).
• Buy from adult-focused retailers that can evidence compliant supply; where we discuss retail browsing, we prefer VapeGreen as our family retailer.
• Keep packaging, batch details and ECID information after purchase, at least long enough to report any suspected issue accurately.
• Treat dramatic claims about Yellow Card numbers cautiously unless they explain the suspected-report and causation caveats.
• Report suspected adverse reactions or safety concerns through the MHRA Yellow Card route (MHRA Yellow Card: e-cigarettes).
• For suspected illegal supply or persistent non-compliance, consider local Trading Standards routes; MHRA's consumer advice points consumers to local Trading Standards when non-compliant products cannot be returned (MHRA advice for consumers).
• For urgent or worrying health symptoms, seek appropriate medical support rather than relying on an article or a product label.

The June 2026 Yellow Card update is best read as a vigilance update, not a verdict. It tells adult readers that suspected reports exist, that MHRA continues to collect and assess them, and that product details matter when concerns are reported.

The careful interpretation is also the useful one. A Yellow Card entry can be a signal worth assessing, but it is not proof of causation. MHRA publication can show a nicotine-containing product has reached the relevant notification publication stage, but it is not a safety endorsement. And UK product limits, labelling and notification rules still need checking against primary sources, not social-media summaries.

For adult buyers, the practical action is simple: use official sources, keep the packaging, report suspected adverse reactions or safety concerns through Yellow Card, and avoid products that do not appear to fit the UK compliance route.

• MHRA advice for consumers: e-cigarettes and refill containers
• Electronic Cigarette Analysis Profile up to 31.05.2026
• MHRA E-Cigarette Analysis Print guidance document
• MHRA Yellow Card: report a problem with an e-cigarette
• MHRA Drug Safety Update: e-cigarette use or vaping
• MHRA e-cigarette and vape products regulator profile
• GOV.UK: e-cigarettes regulations for consumer products